Eric Jnoff
UCB Pharma (Belgium) · 38 works · 1,011 citations · h-index 10
Top works
- Asymmetric Diels−Alder Reactions of 2-Azadienes Catalyzed by a Chiral Copper(II) Complex. A General Route to Enantiomerically Pure Piperidones
- SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids
- Binding Mode and Structure–Activity Relationships around Direct Inhibitors of the Nrf2–Keap1 Complex
- A highly efficient multicomponent synthesis of pyridones and pyrimidones by a [2+2+2] strategy
- Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
- Multicomponent Reactions for the Synthesis of Complex Piperidine Scaffolds
- Discovery of Heterocyclic Nonacetamide Synaptic Vesicle Protein 2A (SV2A) Ligands with Single‐Digit Nanomolar Potency: Opening Avenues towards the First SV2A Positron Emission Tomography (PET) Ligands
- Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain
- Bifunctional bis(oxazolines) as potential ligands in catalytic asymmetric reactions
- Turning high-throughput structural biology into predictive inhibitor design
- Penicillamine as a ligand in the catalytic asymmetric reduction of ketones
- Multicomponent Reactions for the Synthesis of Complex Piperidine Scaffolds
- Identification of ß‐Glucocerebrosidase Activators for Glucosylceramide hydrolysis
- Discovery of a small molecule modulator of the Kv1.1/Kvβ1 channel complex that reduces neuronal excitability and in vitro epileptiform activity
- Discovery of UCB9386: A Potent, Selective, and Brain-Penetrant Nuak1 Inhibitor Suitable for In Vivo Pharmacological Studies
- Discovery of Selective Alpha2CAdrenergic Receptor Agonists
- Inside Cover: Binding Mode and Structure–Activity Relationships around Direct Inhibitors of the Nrf2–Keap1 Complex (ChemMedChem 4/2014)
- Back-up strategies in drug discovery: what, how and when?
- 5:00 PM NEGATIVE MODULATION OF THE SYNAPTIC VESICLE PROTEIN (SV2A): A NEW PHARMACOLOGICAL TARGET FOR COGNITIVE DEFICIT ASSOCIATED WITH SCHIZOPHRENIA
- Advantageous safety profile of a dual selective alpha2C agonist/alpha2A antagonist antinociceptive agent